Skip to main content
Log in

Phase 11 study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation

Preliminary report

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Seventeen patients with malignant gliomas recurrent after chemotherapy and/ or radiation failure were treated with aziridinylbenzoquinone (AZQ) at a dose of 20-15 mg/M2 weekly for four weeks followed by a two week rest. Regression of disease was observed in four patients, 4/17 (24%) for 35, 15+,40+, and 10 weeks. Toxicity was limited to moderate reversible myelosuppression. AZQ in this dose and schedule has limited but definite activity in patients with malignant gliomas progressive after primary radiation therapy failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Driscoll JS, Dudeck L, Congleton G, Geran RI: Potential CNS antitumor agents VI: Aziridinylbenzoquinones III. J Pharm Sci 68:185–188, 1979.

    Google Scholar 

  2. Baker LH, Samson M, Leichman C, Young J: Phase I evaluation of aziridinylbenzoquinones (NSC-182986) in a weekly IV. schedule. Proc AACR 22:189, 1981.

    Google Scholar 

  3. Levin VA, Wilson CB, Crafts D, Norman D, Hoffer P, Spire JP: Criteria for evaluating malignant brain tumor patients undergoing chemotherapy. J of Neurosurgery 47:325–329, 1977.

    Google Scholar 

  4. Eagen RT, Dinapoli RP, Hermann RC, Groover RV, Layton DD: Preliminary communication-treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ; NSC-182986). Am J Clin Oncol. 6: 557–578, 1983.

    Google Scholar 

  5. Feun LG, Savaraj N, Bedirian AY et al.: Phase II study of 2, 5-diaziridinyl-3, 6-bis-carboethoxyamino-1, 4-benzoquinone (AZQ, NSC-182–986) in recurrent malignant gliomas. Proc Am Assoc Cancer Res 23:15, 1982.

    Google Scholar 

  6. Taylor S: Phase II trial of AZQ (Azioidinylbenzoquine; NSC-182986) in malignant gliomas. Southwest Oncology Group, personal, communication.

  7. Feun LG, Yung W-KA, Leavens M E et al.: A phase II trial of 2,5,-diaziridinyl 3.6-bis (carboethoxy animo) 1,4-benzoquinom (AZQ, NSC 182986) in recurrent primary brain tumors. J Neuro-Oncology 2:13–17, 1984.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Decker, D.A., Al Sarraf, M., Kresge, C. et al. Phase 11 study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. J Neuro-Oncol 3, 19–21 (1985). https://doi.org/10.1007/BF00165167

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00165167

Keywords

Navigation